Acelyrin Stock

acelyrin.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $558MM

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Register To Buy and Sell Shares

For more details on financing and valuation for Acelyrin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Acelyrin’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Acelyrin.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Shao-Lee Lin, MD, PhD
Chief Executive Officer
Robert F. Carey
President
Paul Peloso
Chief Medical Officer
Melanie Gloria
Chief Operating Officer
Gil Labrucherie
Chief Financial Officer
Ron Oyston
Senior Vice President, Human Resources
Marc Kubasak
Vice President, Program Lead & Regulatory Affairs
Brian Wiens
Vice President, Biostatistics and Data Sciences
Terry Bevirt
Vice President, Alliance Management, Clinical & Corporate Quality
Katherine To
Vice President - Clinical Operations
Suzy Buckhalter
Senior Director, Finance & Accounting
Tyler Marciniak
Head of Investor Relations and Communications
Shawn Eisnberg
Vice President, Technical Operations

Board Members

Sean Harper
Kin Insurance
Alan Colowick
Sofinnova Investments
Beth Seidenberg
Westlake Village BioPartners
Dan Becker
Access Biotechnology
Richard Gaster
venBio Partners

News Highlights

Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials
Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.
Updated on: Apr 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.